Feed SDZNY
SD

Sandoz Group AG

SDZNY · OTC

$83.62 +1.74% (+$1.43)
1M -8.79%
Market Cap $36.2B
P/E Ratio 39.36x
Div. Yield 1.22%
ROE 10.40%

Bulios Fair Price

$43.12

48.4% downside

Current Price

$83.62

Undervalued Fair Value Overvalued

According to Bulios Fair Price, SDZNY is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
4/9
Valuation
29 /100
Expensive
P/FCF 44.67x
P/E 39.36x
P/B 3.86x
Growth
44 /100
Stable
FCF growth 0.49%
EPS growth 2.31%
Book val. growth 4,727.61%
Profitability
65 /100
Moderate
Op. margin 15.38%
Gross margin 47.02%
FCF margin 7.27%
Quality
45 /100
Average
ROA 4.17%
ROIC 8.21%
Asset turnover 0.51x
Debt
64 /100
Moderate
Int. coverage 7.75x
Debt/Equity 0.61x
Net debt/EBITDA 2.30x
Stability
74 /100
Stable
Profitable years 6
Beta 0.49x
Rev. volatility 18.16%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about SDZNY
Online

About the company

Sandoz Group AG is a Swiss pharmaceutical company specializing in the production of generic drugs and biosimilar products. Founded in 1886, it is now a part of the Novartis group. Sandoz is one of the global leaders in generics, producing drugs that are identical to original products but more affordable. The company focuses on areas such as oncology, cardiovascular diseases, neurology, and infections. Sandoz is known for its innovation in biotechnology, providing high-quality, safe, and affordable treatments to patients worldwide.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Richard Saynor

Employees

23,000

Headquarters

Basel

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.